At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Market Closed 01-30 16:00:00 EST
36.52
-0.34
-0.92%
盘后36.52
+0.000.00%
18:30 EST
High37.22Low36.17Vol444.84K
Open36.90D1 Closing36.86Amplitude2.85%
Mkt Cap2.10BTradable Cap1.63BTotal Shares57.60M
T/O16.25MT/O Rate1.00%Tradable Shares44.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  01-29 09:20
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  01-21
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences : Needham Raises Target Price to $46 From $42
THOMSON REUTERS  ·  01-20
Harmony Biosciences : Needham Raises Target Price to $46 From $42
Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  01-13
Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright
BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation
Reuters  ·  01-12
BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation
Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln
THOMSON REUTERS  ·  01-12
Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln
Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026
THOMSON REUTERS  ·  01-12
Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
Reuters  ·  01-12
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
Harmony Biosciences Is Maintained at Buy by Truist Securities
Dow Jones  ·  01-09
Harmony Biosciences Is Maintained at Buy by Truist Securities
Harmony Biosciences price target lowered to $45 from $48 at Truist
TIPRANKS  ·  01-08
Harmony Biosciences price target lowered to $45 from $48 at Truist
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Reuters  ·  01-07
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
Reuters  ·  2025-12-18
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Reuters  ·  2025-12-16
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
Reuters  ·  2025-12-16
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg
THOMSON REUTERS  ·  2025-12-16
Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  2025-12-10
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome
Reuters  ·  2025-12-08
Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome
Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push
Simply Wall St.  ·  2025-12-05
Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push
Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome
Reuters  ·  2025-12-02
Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating
MT Newswires Live  ·  2025-12-01
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--